Pharmacological activity of a Bv8 analogue modified in position 24

R. Lattanzi, P. Sacerdote, S. Franchi, M. Canestrelli, R. Miele, D. Barra, S. Visentin, C. Denuccio, Frank Porreca, M. De Felice, F. Guida, L. Luongo, V. De Novellis, S. Maione, L. Negri

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE The amphibian peptide Bv8 induces potent nociceptive sensitization in rodents. Its mammalian homologue, prokineticin 2 (PROK2), is strongly up-regulated in inflamed tissues and is a major determinant in triggering inflammatory pain. Bv8 and PROK2 activate two closely related GPCRs, PK 1 and PK 2, in a relatively non-selective fashion. To characterize better the roles of the two receptors in hyperalgesia and to obtain ligands whose binding affinity and efficacy differed for the two receptors, we modified the Bv8 molecule in regions essential for receptor recognition and activation. EXPERIMENTAL APPROACH We modified the Bv8 molecule by substituting Trp in position 24 with Ala (A-24) and compared it with Bv8 for binding and activating PK 1 and PK 2 receptors in cell preparations and in affecting nociceptive thresholds in rodents. KEY RESULTS A-24 preferentially bound to PK 2 receptors and activated them with a lower potency (5-fold) than Bv8. When systemically injected, A-24 induced Bv8-like hyperalgesia in rats and in mice, at doses 100 times higher than Bv8. Locally and systemically injected at inactive doses, A-24 antagonized Bv8-induced hyperalgesia. In rat and mouse models of inflammatory and post-surgical pain, A-24 showed potent and long-lasting anti-hyperalgesic activity. Unlike Bv8, A-24 increased β-endorphin levels in mouse brain. CONCLUSIONS AND IMPLICATIONS A-24 induced its anti-hyperalgesic effect in rodents by directly blocking nociceptor PK 1 receptors and by activating the central opioid system and the descending pain control pathway through brain PK 2receptors.

Original languageEnglish (US)
Pages (from-to)950-963
Number of pages14
JournalBritish Journal of Pharmacology
Volume166
Issue number3
DOIs
StatePublished - Jun 2012

Fingerprint

Hyperalgesia
Rodentia
Pharmacology
Pain
Endorphins
Nociceptors
Brain
Amphibians
Opioid Analgesics
Ligands
Peptides

Keywords

  • anti-hyperalgesic effect
  • Bv8
  • Bv8 analogues
  • chemotaxis
  • cytokine release
  • hyperalgesia
  • prokineticin receptors
  • prokineticins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Lattanzi, R., Sacerdote, P., Franchi, S., Canestrelli, M., Miele, R., Barra, D., ... Negri, L. (2012). Pharmacological activity of a Bv8 analogue modified in position 24. British Journal of Pharmacology, 166(3), 950-963. https://doi.org/10.1111/j.1476-5381.2011.01797.x

Pharmacological activity of a Bv8 analogue modified in position 24. / Lattanzi, R.; Sacerdote, P.; Franchi, S.; Canestrelli, M.; Miele, R.; Barra, D.; Visentin, S.; Denuccio, C.; Porreca, Frank; De Felice, M.; Guida, F.; Luongo, L.; De Novellis, V.; Maione, S.; Negri, L.

In: British Journal of Pharmacology, Vol. 166, No. 3, 06.2012, p. 950-963.

Research output: Contribution to journalArticle

Lattanzi, R, Sacerdote, P, Franchi, S, Canestrelli, M, Miele, R, Barra, D, Visentin, S, Denuccio, C, Porreca, F, De Felice, M, Guida, F, Luongo, L, De Novellis, V, Maione, S & Negri, L 2012, 'Pharmacological activity of a Bv8 analogue modified in position 24', British Journal of Pharmacology, vol. 166, no. 3, pp. 950-963. https://doi.org/10.1111/j.1476-5381.2011.01797.x
Lattanzi R, Sacerdote P, Franchi S, Canestrelli M, Miele R, Barra D et al. Pharmacological activity of a Bv8 analogue modified in position 24. British Journal of Pharmacology. 2012 Jun;166(3):950-963. https://doi.org/10.1111/j.1476-5381.2011.01797.x
Lattanzi, R. ; Sacerdote, P. ; Franchi, S. ; Canestrelli, M. ; Miele, R. ; Barra, D. ; Visentin, S. ; Denuccio, C. ; Porreca, Frank ; De Felice, M. ; Guida, F. ; Luongo, L. ; De Novellis, V. ; Maione, S. ; Negri, L. / Pharmacological activity of a Bv8 analogue modified in position 24. In: British Journal of Pharmacology. 2012 ; Vol. 166, No. 3. pp. 950-963.
@article{827145bfbc47435a9b1dfa1cf352b1ff,
title = "Pharmacological activity of a Bv8 analogue modified in position 24",
abstract = "BACKGROUND AND PURPOSE The amphibian peptide Bv8 induces potent nociceptive sensitization in rodents. Its mammalian homologue, prokineticin 2 (PROK2), is strongly up-regulated in inflamed tissues and is a major determinant in triggering inflammatory pain. Bv8 and PROK2 activate two closely related GPCRs, PK 1 and PK 2, in a relatively non-selective fashion. To characterize better the roles of the two receptors in hyperalgesia and to obtain ligands whose binding affinity and efficacy differed for the two receptors, we modified the Bv8 molecule in regions essential for receptor recognition and activation. EXPERIMENTAL APPROACH We modified the Bv8 molecule by substituting Trp in position 24 with Ala (A-24) and compared it with Bv8 for binding and activating PK 1 and PK 2 receptors in cell preparations and in affecting nociceptive thresholds in rodents. KEY RESULTS A-24 preferentially bound to PK 2 receptors and activated them with a lower potency (5-fold) than Bv8. When systemically injected, A-24 induced Bv8-like hyperalgesia in rats and in mice, at doses 100 times higher than Bv8. Locally and systemically injected at inactive doses, A-24 antagonized Bv8-induced hyperalgesia. In rat and mouse models of inflammatory and post-surgical pain, A-24 showed potent and long-lasting anti-hyperalgesic activity. Unlike Bv8, A-24 increased β-endorphin levels in mouse brain. CONCLUSIONS AND IMPLICATIONS A-24 induced its anti-hyperalgesic effect in rodents by directly blocking nociceptor PK 1 receptors and by activating the central opioid system and the descending pain control pathway through brain PK 2receptors.",
keywords = "anti-hyperalgesic effect, Bv8, Bv8 analogues, chemotaxis, cytokine release, hyperalgesia, prokineticin receptors, prokineticins",
author = "R. Lattanzi and P. Sacerdote and S. Franchi and M. Canestrelli and R. Miele and D. Barra and S. Visentin and C. Denuccio and Frank Porreca and {De Felice}, M. and F. Guida and L. Luongo and {De Novellis}, V. and S. Maione and L. Negri",
year = "2012",
month = "6",
doi = "10.1111/j.1476-5381.2011.01797.x",
language = "English (US)",
volume = "166",
pages = "950--963",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Pharmacological activity of a Bv8 analogue modified in position 24

AU - Lattanzi, R.

AU - Sacerdote, P.

AU - Franchi, S.

AU - Canestrelli, M.

AU - Miele, R.

AU - Barra, D.

AU - Visentin, S.

AU - Denuccio, C.

AU - Porreca, Frank

AU - De Felice, M.

AU - Guida, F.

AU - Luongo, L.

AU - De Novellis, V.

AU - Maione, S.

AU - Negri, L.

PY - 2012/6

Y1 - 2012/6

N2 - BACKGROUND AND PURPOSE The amphibian peptide Bv8 induces potent nociceptive sensitization in rodents. Its mammalian homologue, prokineticin 2 (PROK2), is strongly up-regulated in inflamed tissues and is a major determinant in triggering inflammatory pain. Bv8 and PROK2 activate two closely related GPCRs, PK 1 and PK 2, in a relatively non-selective fashion. To characterize better the roles of the two receptors in hyperalgesia and to obtain ligands whose binding affinity and efficacy differed for the two receptors, we modified the Bv8 molecule in regions essential for receptor recognition and activation. EXPERIMENTAL APPROACH We modified the Bv8 molecule by substituting Trp in position 24 with Ala (A-24) and compared it with Bv8 for binding and activating PK 1 and PK 2 receptors in cell preparations and in affecting nociceptive thresholds in rodents. KEY RESULTS A-24 preferentially bound to PK 2 receptors and activated them with a lower potency (5-fold) than Bv8. When systemically injected, A-24 induced Bv8-like hyperalgesia in rats and in mice, at doses 100 times higher than Bv8. Locally and systemically injected at inactive doses, A-24 antagonized Bv8-induced hyperalgesia. In rat and mouse models of inflammatory and post-surgical pain, A-24 showed potent and long-lasting anti-hyperalgesic activity. Unlike Bv8, A-24 increased β-endorphin levels in mouse brain. CONCLUSIONS AND IMPLICATIONS A-24 induced its anti-hyperalgesic effect in rodents by directly blocking nociceptor PK 1 receptors and by activating the central opioid system and the descending pain control pathway through brain PK 2receptors.

AB - BACKGROUND AND PURPOSE The amphibian peptide Bv8 induces potent nociceptive sensitization in rodents. Its mammalian homologue, prokineticin 2 (PROK2), is strongly up-regulated in inflamed tissues and is a major determinant in triggering inflammatory pain. Bv8 and PROK2 activate two closely related GPCRs, PK 1 and PK 2, in a relatively non-selective fashion. To characterize better the roles of the two receptors in hyperalgesia and to obtain ligands whose binding affinity and efficacy differed for the two receptors, we modified the Bv8 molecule in regions essential for receptor recognition and activation. EXPERIMENTAL APPROACH We modified the Bv8 molecule by substituting Trp in position 24 with Ala (A-24) and compared it with Bv8 for binding and activating PK 1 and PK 2 receptors in cell preparations and in affecting nociceptive thresholds in rodents. KEY RESULTS A-24 preferentially bound to PK 2 receptors and activated them with a lower potency (5-fold) than Bv8. When systemically injected, A-24 induced Bv8-like hyperalgesia in rats and in mice, at doses 100 times higher than Bv8. Locally and systemically injected at inactive doses, A-24 antagonized Bv8-induced hyperalgesia. In rat and mouse models of inflammatory and post-surgical pain, A-24 showed potent and long-lasting anti-hyperalgesic activity. Unlike Bv8, A-24 increased β-endorphin levels in mouse brain. CONCLUSIONS AND IMPLICATIONS A-24 induced its anti-hyperalgesic effect in rodents by directly blocking nociceptor PK 1 receptors and by activating the central opioid system and the descending pain control pathway through brain PK 2receptors.

KW - anti-hyperalgesic effect

KW - Bv8

KW - Bv8 analogues

KW - chemotaxis

KW - cytokine release

KW - hyperalgesia

KW - prokineticin receptors

KW - prokineticins

UR - http://www.scopus.com/inward/record.url?scp=84860860459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860860459&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2011.01797.x

DO - 10.1111/j.1476-5381.2011.01797.x

M3 - Article

C2 - 22122547

AN - SCOPUS:84860860459

VL - 166

SP - 950

EP - 963

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 3

ER -